Key facts
- This page summarizes Brian Clark McCarthy's Form 4 filing for OptimizeRx Corp (OPRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Aug 2024, 17:22.
Brian Clark McCarthy - 02 Aug 2024 Form 4 Insider Report for OptimizeRx Corp (OPRX)
- Reporting relationship
- Chief Revenue Officer
- Issuer ticker
- OPRX
- Reported as of
- 02 Aug 2024
- Net transaction value
- $0
- Reporting owner signature
- /s/ Marion Odence-Ford, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Brian Clark McCarthy filed Form 4 for OptimizeRx Corp (OPRX) on 05 Aug 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OPRX
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +18,677
- Change %
- Price
- $0.000000
- Shares after
- 18,677
- Date
- 02 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,677
- Exercise price
- $10.49
- Footnotes
- F1
OPRX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +9,533
- Change %
- Price
- $0.000000
- Shares after
- 9,533
- Date
- 02 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,533
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Stock Option will vest 1/3 at the end of each anniversary from issuance.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of OptimizeRx's common stock. The restricted stock units will vest 1/3 at the end of each anniversary from issuance. Any restricted stock unit that has not been earned and vested as of the third anniversary of the grant date will be forfeited. Vesting of the restricted stock units shall accelerate upon a qualifying termination.
SEC remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.